Online inquiry

IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10928MR)

This product GTTS-WQ10928MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10928MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15840MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ12944MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ4208MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ11865MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-7684
GTTS-WQ5144MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ3237MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ517MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ4116MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW